↓ Skip to main content

Cochrane Database of Systematic Reviews

Dopamine agonists for the treatment of cocaine dependence

Overview of attention for article published in Cochrane database of systematic reviews, May 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)

Mentioned by

1 X user
5 Wikipedia pages
1 YouTube creator


60 Dimensions

Readers on

258 Mendeley
Dopamine agonists for the treatment of cocaine dependence
Published in
Cochrane database of systematic reviews, May 2015
DOI 10.1002/14651858.cd003352.pub4
Pubmed ID

Silvia Minozzi, Laura Amato, Pier Paolo Pani, Renata Solimini, Simona Vecchi, Franco De Crescenzo, Piergiorgio Zuccaro, Marina Davoli


Cocaine misuse is a disorder for which no pharmacological treatment of proven efficacy exists. Advances in neurobiology could guide future medication development. To investigate the efficacy and acceptability of dopamine agonists alone or in combination with any psychosocial intervention for the treatment of of people who misuse cocaine. We run the search on 12 January 2015. We searched the Cochrane Drugs and Alcohol Group (CDAG) Specialized Register, PubMed, EMBASE, CINAHL, PsycINFO, ICTRP, clinicaltrials.gov and screened reference lists. Randomised controlled trials (RCTs) and controlled clinical trials (CCTs) comparing dopamine agonists alone or associated with psychosocial intervention with placebo, no treatment or other pharmacological interventions. We used standard Cochrane methodological procedures. Twenty four studies, including 2147 participants, met the inclusion criteria. Comparing any dopamine agonist versus placebo, we found no differences for any of the outcomes considered: dropout (moderate quality of evidence), abstinence (low quality of evidence), severity of dependence (low quality of evidence), adverse events (moderate quality of evidence). This was also observed when single dopamine agonists were compared against placebo. Comparing amantadine versus antidepressants, we found low quality of evidence that antidepressants performed better for abstinence (RR 0.25, 95% CI 0.12 to 0.53) based on two studies with 44 participants. No differences were found for dropout or adverse events, for both moderate quality of evidence.The major flaws of the included studies concerned selection bias because most studies did not report information about sequence generation (80%) and allocation concealment methods (86%): half of the included studies were judged at unclear risk of performance bias and 62.5% at unclear risk of detection bias for what concerns subjective outcomes. Current evidence from RCTs does not support the use of dopamine agonists for treating cocaine misuse. This absence of evidence may leave to clinicians the alternative of balancing the possible benefits against the potential adverse effects of the treatment. Even the potential benefit of combining a dopamine agonist with a more potent psychosocial intervention, which was suggested by the previous Cochrane Review (Soares 2003), is not supported by the results of this Cochrane Review update.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 258 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Brazil 1 <1%
Unknown 256 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 47 18%
Researcher 31 12%
Student > Bachelor 28 11%
Student > Ph. D. Student 26 10%
Other 17 7%
Other 54 21%
Unknown 55 21%
Readers by discipline Count As %
Medicine and Dentistry 82 32%
Psychology 25 10%
Nursing and Health Professions 22 9%
Social Sciences 12 5%
Agricultural and Biological Sciences 11 4%
Other 36 14%
Unknown 70 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 November 2022.
All research outputs
of 25,388,837 outputs
Outputs from Cochrane database of systematic reviews
of 12,525 outputs
Outputs of similar age
of 279,930 outputs
Outputs of similar age from Cochrane database of systematic reviews
of 231 outputs
Altmetric has tracked 25,388,837 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 12,525 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 37.2. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,930 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 231 others from the same source and published within six weeks on either side of this one. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.